- Author:
Xing-Li ZHAO
1
;
Kai-Qi LIU
1
;
Dong LIN
1
;
Hui WEI
1
;
Ying WANG
1
;
Chun-Lin ZHOU
1
;
Bing-Cheng LIU
1
;
Wei LI
1
;
Cheng-Wen LI
1
;
Qing-Hua LI
1
;
Zeng CAO
1
;
Ben-Fa GONG
1
;
Yun-Tao LIU
1
;
Xiao-Yuan GONG
1
;
Yan LI
1
;
Run-Xia GU
1
;
Ying-Chang MI
1
;
Jian-Xiang WANG
2
Author Information
- Publication Type:Journal Article
- MeSH: Humans; Incidence; Karyotype; Karyotyping; Middle Aged; Mutation; Proto-Oncogene Proteins c-kit
- From: Journal of Experimental Hematology 2015;23(2):300-305
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the incidence of karyotypes and gene mutations for elder acute myeloid leukemia and to explore the relationship between each other.
METHODSClinical data and bone marrow samples of elder AML patients were collected. Karyotype and gene mutation (FLT3, NPM1, C-Kit, CEBPα, DNMT3A) test were performed, characteristics of karyotypes and gene mutations were analysed.
RESULTSThe incidence of better risk karyotype was 16.6%, in which the incidences of t(15;17), t(8;21) and inv (16)/t(16;16) were 3.90%, 10.73%, and 1.95% respectively; the incidence of intermediate risk karyotype was 72.2%, in which the incidence of normal karyotype was 57.86%; the incidence of poor risk karyotype was 11.20%, in which the incidence of of MLL/11q23, complex karyotype and monosomal karyotype were 1.95%, 6.34%, 5.85% respectively; the incidences of FLT3, NPM1, C-Kit, CEBPα, DNMT3A mutation were 12.57%, 22.06%, 2.16%, 14.71%, 15.71% respectively. Compared with patients older than 60 years, patients with age of 55-60 years were with less complex karyotype (1.09% vs 10.62%)(P=0.003) and monosomal karyotype (2.17% vs 8.85%)(P=0.032), and more t(8;21)(17.39% vs 5.31%)(P=0.008) and inv (16)/t(16;16)(4.35% vs 0.00%)(P=0.045).
CONCLUSIONFor older AML patients, great difference in the distribution of karyotyes was found between the patients older than 60 years and patients with age of 55-60 years, while no such characteristics was found for gene mutations. Good elucidation of karyotypes and gene mutations are key for the treatment of older acute myeloid leukemia patients.